<DOC>
	<DOC>NCT02068508</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of long-term treatment with pioglitazone (Actos Tablets) in in the routine clinical setting in combination with combination with an insulin product in patients with type 2 diabetes mellitus who responded inadequately when using an insulin product in addition to diet therapy and exercise therapy.</brief_summary>
	<brief_title>Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"</brief_title>
	<detailed_description>This is a special drug use surveillance on long-term use of newly co-administered pioglitazone tablets (Actos Tablets) in patients with type 2 diabetes mellitus who have poorly controlled blood glucose when using an insulin product in addition to diet therapy and exercise therapy; this survey is designed to determine the safety and efficacy of long-term use of pioglitazone tablets (Actos Tablets) in in the routine clinical setting in combination with combination with an insulin product (the planned sample size, 1000.) The usual adult dosage is 15 mg of pioglitazone administered orally once daily before or after breakfast. Dose adjustment will be made according to gender, age, and symptoms with an upper limit of 30 mg.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus assumed to have insulin resistance who responded inadequately when using an insulin product in addition to diet therapy and exercise therapy who meet the following criteria at enrollment. 1. Patients treated with an insulin product for at least 4 weeks 2. Patients who started Actos Tablets for the first time after the start of an insulin product 3. Patients likely to be available for a 52week observation and evaluation after the start of coadministration of Actos Tablets Patients with contraindications to Actos Tables and insulin products treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>